Abstract 87TiP
Background
XB002 is a novel ADC composed of a high-affinity TF-directed human monoclonal antibody conjugated to zovodotin, an auristatin-based payload with a protease-cleavable linker. High TF expression has been observed in many tumor types, including squamous cell carcinoma of head and neck (SCCHN), non–small cell lung cancer (NSCLC), pancreatic, prostate, cervical, endometrial, and epithelial ovarian cancer (EOC), and is associated with poor prognosis. In preclinical studies, XB002 showed encouraging antitumor activity without interfering with coagulation. JEWEL-101 (NCT04925284) is a multicenter, phase 1 first-in-human trial, designed to determine the recommended dose and/or maximum tolerated dose of XB002 alone or in combination with nivolumab or bevacizumab and evaluate safety and antitumor activity in advanced solid tumors. Presented is the design of the cohort expansion stage.
Trial design
The multi-cohort expansion phase of JEWEL-101 will assess the safety, PK, and efficacy of XB002. Patients (pts) must be aged ≥18 years with inoperable, advanced, metastatic, or recurrent tumors, progression during/following last systemic therapy, ECOG PS 0/1, adequate organ and marrow function, and archival or fresh tumor tissue. Prior treatment with TF-targeting or auristatin-based ADCs is not permitted. Pts with significant ocular disorders are excluded. Concomitant anticoagulants are permitted, and pts with peripheral neuropathy not impacting activities of daily living are allowed. Expansion cohorts for single-agent XB002 include NSCLC, EOC, cervical, SCCHN, pancreatic, esophageal SCC, metastatic castration-resistant prostate cancer, triple-negative breast cancer, hormone receptor-positive breast cancer, endometrial cancer, and a tumor-agnostic TF-expressing cohort. Expansion cohorts for combination therapy include NSCLC, SCCHN, and esophageal SCC (XB002 + nivolumab), and EOC (XB002 + bevacizumab). The primary objective is ORR per RECIST v1.1 by investigator. Secondary objectives include safety, PK, immunogenicity, PFS, DOR, and OS. Enrollment is ongoing in the US, Europe, and Asia-Pacific region.
Clinical trial identification
NCT04925284.
Legal entity responsible for the study
Exelixis, Inc.
Funding
This study is funded by Exelixis, Inc.
Disclosure
S. Ulahannan: Financial Interests, Institutional, Research Funding: AbbVie, Inc, Adlai Nortye, ArQule, Inc, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Ciclomed LLC, Erasca, Evelo Biosciences, Inc., Exelixis, G1 Therapeutics, Inc, GSK GSK, IGM biosciences, Incyte, Isofol, Klus Pharma, Inc., Macrogenics, Merck Co. Inc, Mersana Therapeutics, OncoMed Pharmaceuticals, Inc., Pfizer, Regeneron, Inc., Revolution Medicines, Inc., Synermore Biologics Co, Takeda, Tarveda Therapeutics, Tesaro, Tempest, Vigeo Therapeutics Inc.; Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, IgM biosciences. M.L. Johnson: Financial Interests, Institutional, Research Funding: AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, Checkpoint Therapeutics, City of Hope National Medical Center, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Eli Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunitas Therapeutics, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, WindMIL Therapeutics, Y-mAbs Therapeutics; Financial Interests, Institutional, Advisory Role: AbbVie, Amgen, Arcus Biosciences, Arrivent, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Daiichi Sankyo, EcoR1, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Ideaya Biosciences, Immunocore, iTeos, Janssen, Jazz Pharmaceuticals, Merck, Mirati Therapeutics, Molecular Axiom, Novartis, Oncorus, Pyramid Biosciences, Regeneron Pharmaceuticals, Revolution Medicines, Sanofi-Aventis, SeaGen, Synthekine, Takeda Pharmaceuticals, Turning Point Therapeutics, VBL Therapeutics. M.C. Weiss: Financial Interests, Personal, Other, Honoraria: 60 minute telephone survey-topic Management of Soft Tissue Sarcoma-8/23/2022: Research America; Financial Interests, Personal, Advisory Board, SpringWorks Ovarian Dysfunction Advisory Board-3/2/2023: Springworks. A. Vandross: Financial Interests, Personal, Full or part-time Employment: NEXT ONCOLOGY; Financial Interests, Personal and Institutional, Research Funding, PAYMENTS MADE TO COMPANY BY SPONSORS: NEXT ONCOLOGY. S. Vidal-Cardenas: Financial Interests, Personal, Full or part-time Employment: Exelixis, Inc.; Financial Interests, Personal, Stocks/Shares: Exelixis, Inc. M. Syed: Financial Interests, Personal, Full or part-time Employment: Exelixis, Inc.; Financial Interests, Personal, Stocks/Shares: Exelixis, Inc. A.W. Tolcher: Financial Interests, Personal, Full or part-time Employment: NEXT Oncology; Financial Interests, Personal, Leadership Role: NEXT Oncology; Financial Interests, Personal, Leadership Role, On the NEXT Oncology Board: NEXT Oncology; Financial Interests, Personal and Institutional, Advisory Role, Fees for consulting and advisory board memberships for Dr. Anthony Tolcher are paid to New Experimental Therapeutics, LLC d/b/a NEXT Oncology of which he is President and Founder.: ABBVIE, Inc, Aclaris Therapeutics, AGENUS, Inc., asana biosciences, Ascentage, Axlmmune, Bayer, Blu Print Oncology, Daiichi Sankyo, Inc., gilde healthcare partners, hbm partners, idea Pharma, Immuneering, Immunomet Therapeutics, Inc., Impact Therapeutics US, Inc., Karma Oncology B.V., Kirilys Therapeutics, Inc., Lengo Therapeutics, Inc., Link Immunotherapeutics, Mekanistic Therapeutics, Menarini Ricerche, Mersana, NANOBIOTIX, Novo Nordisk Inc., NervianoMedical Sciences S.r.I. (NMS), Nurix Therapeutics, Ocellaris Pharma, Inc. & Eli Lilly, Partner Therapeutics, Pfizer Inc., Qualigen Therapeutics, PIERRE FABRE, Roche, RYVU therapeutics, Seattle Genetics, SK Life Science, SOTIO Biotechnology Co., Spirea Limited Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, Transcenta Therapeutics Inc., Transgene, Trillium Therapeutics Inc., Verastem Oncology, VRISE Therapeutics, Inc., Zentalis Pharmaceuticals; Financial Interests, Personal and Institutional, Expert Testimony, Fees for consulting and advisory board memberships for Dr. Anthony Tolcher are paid to New Experimental Therapeutics, LLC d/b/a NEXT Oncology of which he is President and Founder.: Immunogen; Financial Interests, Personal and Institutional, Proprietary Information, Fees for consulting and advisory board memberships for Dr. Anthony Tolcher are paid to New Experimental Therapeutics, LLC d/b/a NEXT Oncology of which he is President and Founder.: Ascentage Pharma, Zentalis; Financial Interests, Personal and Institutional, Advisory Board, Fees for consulting and advisory board memberships for Dr. Anthony Tolcher are paid to New Experimental Therapeutics, LLC d/b/a NEXT Oncology of which he is President and Founder.: ADAGENE, Inc., aro biotherapeutics, BIOINVENT, Boehringer Ingelheim International GmbH, Bright Peak Therapeutics, Deka Biosciences, Eleven Bio, ELUCIDA, emd serono/ Merck KGaA, Hiber Cell, Inc., Ikena Oncology, IMMUNOME, Janssen Global Services, LLC, nbe therapeutics, Pelican, JAZZ, Pieris Pharma, PYXIS Oncology, Senti Biosciences, Vincerx, ZielBio, Inc., Zymeworks Biopharmaceuticals Inc., MIRATI, Roche.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract